Recent Updates
Recently added Catalysts

CLBS03

Phase 2

Diabetes Mellitus | Biologics | Metabolic |Lisata Therapeutics, Inc.|Trials Updated: Jan 8, 2021

CLBS03 target and mechanism

ModalityBiologics

Also known as CLBS03 Low Dose

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials1
Total Enrollment113

FDA Designations

No designations recorded

CLBS03 clinical trials

CLBS03 · 1 trial · 1 indication

Phase 2 1
NCT02691247Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)Diabetes Mellitus
COMPLETED113 Analytics
PHASE2COMPLETED
Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)
Diabetes MellitusUnlock trial analytics

Study Endpoints

Primary Endpoints

Change From Baseline in 4-hour Mixed Meal Tolerance Test (MMTT)-Stimulated C-peptide Area Under the Curve (AUC) at Week 52
Week 52

The area-under-curve of sequential C-peptide concentrations (AUC-Cpep) during the mixed-meal tolerance test (MMTT) is the gold-standard method to assess residual beta-cell (ie, insulin) secretion in type 1 diabetes.

Secondary Endpoints

Change From Baseline in 4-hour Mixed Meal Tolerance Test (MMTT)-Stimulated C-peptide Area Under the Curve (AUC) at Week 104
Week 104
Change in Hemoglobin A1c (HbA1c)
Week 104
Change From Baseline in Mean Daily Dose of Insulin
Week 104
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelFACTORIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
CLBS03 Low DoseEXPERIMENTALA single infusion of CLBS03 Low Dose, a cell product comprised of autologous, ex vivo expanded regulatory T-cells resuspended in sterile USP (United States Pharmacopoeia) infusion solution.
CLBS03 High DoseEXPERIMENTALA single infusion of CLBS03 High Dose, a cell product comprised of autologous, ex vivo expanded regulatory T-cells resuspended in sterile USP infusion solution.
PlaceboPLACEBO_COMPARATORA single infusion of placebo, consisting of the infusion solution only

Interventions

NameTypeDescription
CLBS03 Low DoseBIOLOGICAL -
CLBS03 High DoseBIOLOGICAL -
PlaceboBIOLOGICAL -
Unlock Study Design Details

Eligibility Criteria

Age Range8 Years to 17 Years
SexALL
Healthy VolunteersNo
Study Sites15

Inclusion Criteria: * Male and females aged 8 to 17 years of age * Diagnosis of T1DM within 100 days of receipt of study drug * Positive for at least one islet cell autoantibody * Peak MMTT-stimulated C-peptide level \> 0.2 pmol/mL (at the screening visit) * Weight of ≥30 kg * Must agree to use a r...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about CLBS03

What is CLBS03?

CLBS03 is an investigational biologic developed by Lisata Therapeutics, Inc. for diabetes mellitus. It is a Phase 2 cell therapy candidate studied in adolescents with recent onset type 1 diabetes. CLBS03 is also known as CLBS03 Low Dose.

What is CLBS03 used for in diabetes mellitus?

CLBS03 was studied for the treatment of type 1 diabetes in adolescents with recent onset disease. Its Phase 2 trial enrolled patients aged 8 years and older in the United States to evaluate safety and efficacy in this population.

Who makes CLBS03?

CLBS03 is developed by Lisata Therapeutics, Inc., which trades under the ticker LSTA. The company sponsored the Phase 2 clinical program evaluating CLBS03 in adolescents with recent onset type 1 diabetes.

What phase is CLBS03 in?

CLBS03 is in Phase 2 development and is investigational. Its single Phase 2 trial, the Sanford Project T-Rex Study, has been completed. CLBS03 has not been established as an approved therapy.

What clinical trials is CLBS03 in?

CLBS03 has been evaluated in one clinical trial, NCT02691247, titled Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study). The Phase 2 trial was completed and enrolled 113 participants in the United States.

Is CLBS03 the same as CLBS03 Low Dose?

Yes, CLBS03 Low Dose is an alternative name for CLBS03. Readers searching either name are referring to the same investigational Lisata Therapeutics biologic being studied in type 1 diabetes.